



LIFESTARS

★ ★ ★ ★ ★

EXECUTIVE AWARDS DINNER AND CEREMONY

WINNERS BROCHURE

19 November 2019 | Honourable Artillery Company | London



Hosted by



The network
for life science
executive leaders

#lifestarsawards



The annual, **European Lifestars Awards** bring together hundreds of European life science leaders, investors, partners and deal makers, and is a celebration of the success stories, breakthroughs, transactions and transformational deals and the people, teams and organisations that have played a critical role in the advancement of the industry over the previous 12 months.

19 highly coveted awards including an Industry Contribution Award and Life-time Achievement Award were presented during the evening ceremony on the 19th November 2019, centred within a champagne reception, evening entertainment, gala dinner and post-show celebration and networking.

The year's finalist roster were assessed and voted upon by a committee of over 65 judges during a 4-month schedule stretching back to June. The judging faculty were chosen for their wealth of industry experience and strength of their cross-border knowledge and are selected from a geographically diverse pool of industry stakeholders.

The European Lifestars Awards are instrumental in highlighting the incredible work being carried out across the European life science value chain and we were delighted to be recognising their achievements.

View the [2019 Photo Gallery here](#).

Evening schedule

6.15pm - Reception, Silent Auction bidding and Charity Raffle ticket purchase

7.30pm - Seated Gala Dinner

9.15pm - Official Charity Presentation and Raffle draw

9.25pm - Evening Entertainment

9.40pm - Awards ceremony hosted by Comedian, Presenter and Writer Ellie Taylor

11.00pm - Silent Auction lots announced, post show bar and networking

12.00am - Close of evening

CO-HOST PARTNER

Jefferies

AWARD CATEGORY PARTNERS



BNY MELLON

DFIN

Jefferies

Kempen



LONGEVITY
LEADERS

M

MINTZ



morgan prestwich
Life Sciences Executive Search



MSD
INVENTING FOR LIFE

Nasdaq

NDA

Talentmark
The Life in Science

FESTIVAL GOERS. CLIMATE ACTIVISTS. HARDCORE GAMERS. FUTURE LEADERS.

**7 young people are
told they have cancer
every day.**



**WE'VE GOT
THEIR BACKS.**

www.teenagecancertrust.org



Teenage Cancer Trust is a registered charity: 1062559 (England & Wales); SC039757 (Scotland)



2019 AWARDS CHARITY



We were delighted to be exclusively raising donations via the official Awards Raffle in aid of the Teenage Cancer Trust.

Guest support of the on-the-night Awards Prize Raffle will play a vital role in helping young people with cancer for years to come.

Liz Tait, Director of Fundraising at the Teenage Cancer Trust was the charity representative speaking during the dinner and drawing the raffle prizes.

Donations of £5 from your mobile by texting **NURSE** to **70500** can still be made.

Charity raffle prizes:

- Adidas Originals Trainers (Blue / White, 9.5) signed by Noel Gallagher
- A pair of tickets to TCT @ Royal Albert Hall (dated 23rd–29th March 2020)
- 3-Course Lunch for 2 at 3* Michelin Restaurant Gordon Ramsay
- Beats by Dre Solo 3 On-Ear Wireless Headphones
- Fitbit Charge 3 Fitness Tracker
- Le Dame de Pic, newly crowned 2* Michelin Restaurant Voucher (worth £100)
- 3rd Generation Amazon Echo Smart Speaker

The Awards were also working with GiveFundraising to raise additional proceeds for Teenage Cancer Trust through the onsite Charity Silent Auction.

GiveFundraising™
Helping you raise more





Gil Star-Melton
Managing Director, Global Healthcare Investment Banking Group
Jaffres LLC



Nicholas Moore
Managing Director, Healthcare
Sitel



Thomas Stockman
Managing Director, Healthcare
RBC Capital Markets



Greg Bell
COO
Morgan Perleberg



Jonathan Krasner
Chair, Securities & Capital Markets Practice
Mintz



Ian Oliver
Audit Partner - Life Sciences Sector Specialist
KPMG



Giovanni Marzulli
Partner
Medall



Jonathan Tobin
Investment Director
Aqua BioScience plc



Ben Thorge
Head of Healthcare Banking, EMEA
Goldman Sachs



Gabriel P. Casazza
Managing Director, Investment Banking
TVB Loomis



Araf El-Hamrouni
Managing Director EMEA
Nasdaq



Tim Lister
Senior Director, Emerging Technology & Innovation, Business Development
R&L Life & Company



Natalie van Wieringen
Kunming Lead, Worldwide Business Development
Pflanz



Graziano Taglietti
Managing Partner
Sofusano Partners



Elisa Perini
Partner
Brenco Ltd



Johan Klerfeld
Senior Partner
Lundbeckfonden Venture



Stephanie Van Heyde
Head, Equity and Bond Syndicate
RBC Securities



Jan de Kerpel
Managing Director, Life Sciences & Healthcare
Komen & Co



Paul L'Abbe
Head, European Innovation Hub
MSD



Anna Williamson
Director, Oncology Business Development & Head of UK Business Development
Concentrix Partnering



David Steffen
Principal
Horowitz Ventures Fund



Ruel Bulthuis
Managing Director
BNP Paribas



David O'Mahony
Partner
Sandoz Life Sciences



Diana Sarawad
Founder and Managing Partner
Proxima Partners



David Mosher
Managing Director, Oncology Biotech
BNY Mellon



Ray Winters
Managing Director, EMEA Healthcare Investment Banking
Bank of America Merrill Lynch



Christopher Cae
EVP, Executive Search
Talentart



Nicola Scott
Head, New Ventures & Transactions
Johnson & Johnson Innovation



Sam Taylor
Partners, Technology, Industry Hub, London
PwC United Kingdom



Flores de Hemptone
Venture Partner
ICB Ventures



Jean-François Meun
Principal, Life Sciences
Aplicance



Sander Houtweg
Managing Partner
Pflanz



Deborah Harland
Partner
SR One



Christopher Rosell
Partner
Allison Capital



Jerry Safarik
Managing Partner
Aurion Partners



Jennifer Beckwith
Partner, Corporate and M&A
Frederick Bruckhaus Designer



Stephanie McGeath
Partner
Goodwin Law



Richard Anderson
Managing Partner
ICAD Communications Ltd



Jeffrey Gorkovskiy
CEO
MEDA Group



Madeline Armstrong
Senior Editor
Ventage



Julia Weinberger-van Wieringen
Investment Manager
LIP



Rob de Roo
Operating Partner
BioGeneration Ventures



Julia Tondos
Chief Commercial Officer
Sengen International



Roshni McLaren
COO
Latham & Wootles



Chris Giammus
Head of Equity Capital, Ireland
Euronext



Chris Gardner
Partner
Correlation Communications



Jill Ogden
Principal
Medica Associates



Catherine Longworth
Senior Reporter, Medibook Knight
Informa Pharma Intelligence



Claudio Bonazzi
Partner
Imagot SGR



Arvid Kallenberg-Hansen
Managing Partner - Healthcare
HofmannIT Partners



Vivian Buhli
Director, Strategy and Transactions
Sengen Health Consulting



Hector de Hemptone
Partner and Global Co-Chair, Life Sciences Sector
DLA Piper



Sam Charles
Managing Partner, Life Sciences
Induct Partners



Laura Giddens
Managing Director
TVM Communications



Rene Johnson
Managing Director, Global Capital Markets
Dowling Financial Services



Jennifer Smith-Parker
Senior Editor
GlobalData



Patrick Schuchel
Investment Manager
Induct Partners



Eduardo Hegrest
Co-Founder and Managing Partner
Aurion-IT



Patricia Hurley
Partner
PFD Consulting



James Gubbins
Partner
Covington & Burling LLP



Mary Clark
Managing Director, Communications
Quintum Strategic Communications



Fraser Hall
Senior Director
Oligate Drug Expansion



Lisa Grayson
Editor
Ventage



Steve Carney
Editor - Drug Discovery Today
Bioscience



Comedian, actor, and writer Ellie Taylor's latest stand-up show 'Don't Got This' toured nationwide in 2019. She was one of 5 UK comedians to be featured in Netflix's trailblazing 'Comedians of the World' series, with her special 'Cravings' premiering on New Year's Day 2019.

Ellie is part of the core cast of hit BBC 2 satirical show 'The Mash Report', with her clips becoming worldwide viral hits, notching up close to 60 million views online.

Further TV credits include Mock the Week (BBC 2), Qi (BBC 2) and she has hosted Live at the Apollo (BBC 2). She regularly appears on BBC Radio 4's 'The Now Show' and acting credits include Gloria in ITV2's 'Plebs' and Poppy in Comedy Central's 'Brotherhood'.

SEED-STAGE FINANCE RAISE OF THE YEAR - hosted by MSD

SERIES A FINANCE RAISE OF THE YEAR - hosted by Morgan Prestwich

SERIES B FINANCE RAISE OF THE YEAR - hosted by Nasdaq

IPO OF THE YEAR - hosted by Kempen

POST-IPO EQUITY RAISE OF THE YEAR - hosted by BNY Mellon

VC FIRM OF THE YEAR - hosted by Inv€stival Showcase

DEAL OF THE YEAR (<£500M) - hosted by LSX Leaders

DEAL OF THE YEAR (>£500M) - hosted by LSX Leaders

M&A DEAL OF THE YEAR - hosted by Mintz

PHARMA BD TEAM OF THE YEAR - hosted by Teenage Cancer Trust

CLINICAL TRIAL OF THE YEAR - hosted by NDA Group

CRO OF THE YEAR - hosted by LSX Leaders

BIOTECH COMPANY OF THE YEAR - hosted by MSD

MEDTECH COMPANY OF THE YEAR - hosted by Talentmark


HEALTHTECH COMPANY OF THE YEAR - hosted by DFIN

PRIVATE COMPANY CEO OF THE YEAR - hosted by Jefferies

PUBLIC COMPANY CEO OF THE YEAR - hosted by Jefferies

INDUSTRY CONTRIBUTION AWARD - hosted by LSX Leaders

LIFETIME ACHIEVEMENT AWARD - hosted by Longevity Leaders



**MSD**

INVENTING FOR LIFE

INVENT WITH US

MSD BUSINESS DEVELOPMENT & LICENSING

MSD is inventing because the world still needs cures for cancer, Alzheimer's disease, HIV, and so many other causes of widespread suffering.

We believe that building strong partnerships is critical to solving these challenging diseases — to help people go on, unburdened, to experience, create and live their best lives.

Together we can invent for life.

Learn more at msdlicensing.com

MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.

Copyright ©2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

All rights reserved. 10-19

**SEED STAGE FINANCE RAISE OF THE YEAR**

Hosted by

**MSD**

INVENTING FOR LIFE

This award recognises a company that has successfully completed a significant, impactful or transformational private fundraising at Seed-Stage.

Qualifying criteria

- Must be a fundraiser by a private company
- Must have raised the funds in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Amount of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of investors attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise
- Company research / technology focus and novelty / meeting unmet need

Highly commended and winner presented by Jill Richardson, Senior Director, Discovery Research, MSD

FINALISTS



Great Science Deserves Great Teams

Global HQ +44 (0)1737 226 644

MorganPrestwich.com

London | Boston | Dublin | Zug



SERIES A FINANCE RAISE OF THE YEAR

Hosted by



This award recognises a company that has successfully completed a significant, impactful or transformational private fundraising at Series A stage.

Qualifying criteria

- Must be a fundraising by a private company
- Must have raised the funds in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Amount of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of investors attracted / reputation of investors reinvesting
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise

Highly commended and winner presented by Greg Bell, CEO, Morgan Prestwich

FINALISTS





Nasdaq corporate services empower business leaders with technology and intelligence to innovate, grow and stay ahead of the changing markets.

We offer an integrated suite of market intelligence, analytics, and collaboration solutions that support investor relations and corporate governance professionals around the globe.

Nasdaq Private Market provides liquidity solutions for today's private securities.



We're proud to sponsor the 2019 European Lifestars Awards.

Nasdaq recognizes the Series B Finance Raise of the Year awarded to a European life science company that has successfully completed a significant, impactful and transformational private fundraising at Series B level.

For inquiries, please contact:
Adam Kostyál, Senior Vice President, Head of Listings – EMEA
adam.kostyal@nasdaq.com
+46 (73) 4497145
www.nasdaq.com



SERIES B FINANCE RAISE OF THE YEAR

Hosted by



This award recognises a company that has successfully completed a significant, impactful or transformational private fundraising at Series B stage.

Qualifying criteria

- Must be a fundraising by a private company
- Must have raised the funds in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Amount of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of investors attracted / reputation of investors reinvesting
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise

Highly commended and winner presented by Adam Kostyál, SVP, EMEA, Nasdaq

FINALISTS



Turning dedication into dazzling prospects

Kempen



... SEE OUR DEALS AT [KEMPEN.COM](https://www.kempen.com)



IPO OF THE YEAR

Hosted by

Kempen

This award recognises a company that has successfully completed a significant, impactful or transformational IPO on any international exchange.

Qualifying criteria

- Can be a primary or secondary listing
- Open to European publicly listed life science companies on any exchange.
- Must have transitioned in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Amount of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of new investor(s) attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise

Highly commended and winner presented by Jan de Kerpel, Managing Director, Head of Life Sciences and Healthcare, Kempen

FINALISTS



#lifestarsawards

LIFESTARS



You don't thrive for 230 years by standing still.

As one of the oldest, continuously operating financial institutions in the world, BNY Mellon has endured and prospered through every economic turn and market move since our founding over 230 years ago. Today, BNY Mellon remains strong and innovative, providing investment management and investment services that help our clients to invest, conduct business and transact with assurance in markets all over the world.

To learn more, visit bnymellon.com.



BNY MELLON



POST-IPO RAISE OF THE YEAR

Hosted by



BNY MELLON

This award recognises a company that has successfully completed a significant, impactful or transformational secondary placement or follow-on equity raise (not debt) on any international exchange.

Qualifying criteria

- Must be a fundraising by a public company
- Must have raised the funds in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Amount and type of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of investor(s) attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise

Highly commended and winner presented by Dave Stueber, MD, Depositary Receipts, BNY Mellon

FINALISTS



calliditas
SPRINT

HANSA
BIOPHARMA

IMMUNICUM
REGENERATION IN IMMUNO-ONCOLOGY

Kiadis pharma

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may be used as a generic term to reference the corporation as a whole and/or its various subsidiaries generally. BNY Mellon will not be responsible for updating any information contained within this material and opinions and information contained herein are subject to change without notice. BNY Mellon assumes no direct or consequential liability for any errors in or reliance upon this material. This material may not be reproduced or disseminated in any form without the prior written permission of BNY Mellon. ©2019 The Bank of New York Mellon Corporation. All rights reserved.

#lifestarsawards

LIFESTARS
★★★★★

INV€STIVAL SHOWCASE™

CONNECTING LIFE SCIENCE & HEALTHCARE COMPANIES WITH CAPITAL

In partnership with

Jefferies

5th Annual Investment Showcase

17 November 2020
Waldorf Hilton | London | UK



VENTURE CAPITAL FIRM OF THE YEAR

Hosted by

INV€STIVAL™
SHOWCASE

This award recognises a European VC firm that has outperformed peers, created value and demonstrated truly outstanding investment decision making.

Qualifying criteria

- Firm must have more than 20% portfolio holdings in healthcare and/or life sciences companies
- Period to be judged is between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Evidence of innovative company creation and deal-making strategies
- Volume of investments made in the qualifying timeline
- Number of lead investments made
- Number / quality of successful exits
- Number / value of new funds raised
- Fund performance and returns to LPs

Highly commended and winner presented by Brooke Roberts, Head of Investor Relations and Networking, LSX Leaders

FINALISTS

ARIX



HEALTHCARE

High-Tech Gründerfonds



medicxi

NOVO

Seventure

LSX | WORLD CONGRESS

STRATEGY, INVESTMENT, PARTNERING &
COMMERCIALISATION FOR LIFE SCIENCE
EXECUTIVE LEADERS



DEAL OF THE YEAR (<£500M)

Hosted by



The network
for life science
executive leaders

This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both companies and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.

Qualifying criteria

- A license, partnership, asset acquisition or alliance between companies
- Total potential deal size must be less than £500m
- Deal to have completed in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal (upfront, milestone and total value)
- Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next 12-months
- Post-deal performance

Highly commended and winner presented by Josh Dance, SVP, LSX Leaders

FINALISTS



6th Annual

4-5 February, 2020
133 Houndsditch | Liverpool St
London | UK



The network
for life science
executive leaders

LSX | NORDIC CONGRESS

STRATEGY, INVESTMENT, PARTNERING
AND DEAL MAKING FOR LIFE SCIENCE
EXECUTIVE LEADERS

3rd Annual Conference

September 2-3, 2020
Nasdaq Offices
Stockholm, Sweden



DEAL OF THE YEAR (>£500M)

Hosted by



The network
for life science
executive leaders

This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both companies and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.

Qualifying criteria

- A license, partnership, asset acquisition or alliance between companies
- Total potential deal size must be greater than £500m
- Deal to have completed in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal (upfront, milestone and total value)
 - Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next 12-months
 - Post-deal performance

Highly commended and winner presented by Josh Dance, SVP, LSX Leaders

FINALISTS



Valuable Partnerships



M&A DEAL OF THE YEAR

We are pleased to sponsor

European Lifestars Awards

and to work with innovators and investors across the industry and around the globe.

Mintz has served the life sciences sector since the 1970s and provides comprehensive industry-specific transactional, intellectual property, regulatory, and litigation solutions to help you meet your business and legal objectives.



MINTZ

mintz.com

Hosted by



This award recognises the teams and organisations who have executed a truly transformational and high value M&A deal for both the company and the wider industry.

Qualifying criteria

- Deal must be an M&A deal NOT a license, partnership or alliance
- Open to private, public companies, pharma, commercial leaders or big tech
- Deal to have completed in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal
- Strength of acquirers existing pipeline / synergy with existing portfolio
- Potential game / industry changing implications within next 12-months
- Post-deal performance

Highly commended and winner presented by William Hicks, Co-Chair, Securities & Capital Markets Practice, Mintz

FINALISTS



**FESTIVAL
GOERS.
CLIMATE
ACTIVISTS.
HARDCORE
GAMERS.
FUTURE
LEADERS.**

**7 young people are
told they have cancer
every day.**



**WE'VE GOT
THEIR BACKS.**

www.teenagecancertrust.org



Teenage Cancer Trust is a registered charity: 1062559 (England & Wales); SC039757 (Scotland)



PHARMA BD TEAM OF THE YEAR

Hosted by



This award recognises the business development team from a pharma or large cap biotech company that has excelled in sourcing, executing and delivering extraordinary and transformational deals that created significant value for consumers, company and shareholders.

Qualifying criteria

- Open to all pharma companies and large cap large cap biotech companies with a market capitalisation that is \$10bn or above.
- Open to all business development teams or cross-company teams on a specific deal / project
- Deal to have completed in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Quality and volume of deals completed
- Achievement of milestones and goals and the overcoming of obstacles
- Uniqueness or novelty of deal strategies/terms and structure
- Strength of team leadership and culture
- How alignment across parties was achieved

Highly commended and winner presented by Liz Tait, Director of Fundraising,
Teenage Cancer Trust

FINALISTS



#lifestarsawards



Optimising the development of innovative medicines



We streamline the global development and commercialisation process to accelerate patient access to important medical therapies.

NDA supported **over 40%** of the new medicinal products that were approved in the EU during the last five years.

Do you want your product approved in the US and EU? Contact us now.



DEVELOPMENT
STRATEGY



REGULATORY
SUPPORT



QUALITY &
COMPLIANCE



SCIENTIFIC
COMMUNICATION



Hosted by



This award recognises a European life science company that has realised a significant milestone in the clinic for a new therapy, drug, diagnostic tool, digital application or medical device.

Qualifying criteria

- Open to private or public biotech companies with a market cap of less than \$10bn
- Clinical breakthrough to have been achieved in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Targeting of unmet medical need
- Key indicators / results / inflection points of clinical development
- Phase / speed / progress through clinical stage
- Innovative trial design / patient centric approach
- Outline of future timelines / value creation

Highly commended and winner presented by Johan Strömquist, CEO, NDA Group

FINALISTS





DIGIHEALTH LEADERS

STRATEGY, INVESTMENT, PARTNERING
AND DEAL-MAKING FOR GLOBAL
DIGITAL HEALTH LEADERS

16-17 November 2020
Central London



CRO OF THE YEAR

Hosted by



The network
for life science
executive leaders

This award recognises a European Contract Research / Contract Commercial Organisation that has delivered truly outstanding and exemplary results for their clients and patients through the execution and completion of game-changing clinical-based programmes.

Qualifying criteria

- Open to all Contract Research / Contract Commercial Organisations with European operations
- Submission relates to activities achieved in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- The range of services provided in niche and core therapeutic areas
- Methods of performance improvement or introduction of new services
 - Attention to and quality of relationships with clients
- Progression / outcomes of pre-clinical and clinical programmes
- Building and maintaining existing and long term partnerships

Highly commended and winner presented by Neil Darkes, Co-Founder and Co-CEO,
LSX Leaders

FINALISTS



**MSD**

INVENTING FOR LIFE

INVENT WITH US

MSD BUSINESS DEVELOPMENT & LICENSING

MSD is inventing because the world still needs cures for cancer, Alzheimer's disease, HIV, and so many other causes of widespread suffering.

We believe that building strong partnerships is critical to solving these challenging diseases — to help people go on, unburdened, to experience, create and live their best lives.

Together we can invent for life.

Learn more at msdlicensing.com

MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.

Copyright ©2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

All rights reserved. 10-19

**BIOTECH COMPANY OF THE YEAR**

Hosted by

**MSD**

INVENTING FOR LIFE

This award recognises a European Biotech (drug discovery, pre-clinical, clinical, OTM therapeutic) company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community.

Qualifying criteria

- Open to all Biotech therapeutic companies with European Headquarters
- Open to all biotech companies with a market capitalisation that is \$10bn or less.
- Submission relates to activities achieved in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Targeting of unmet medical need / use of innovative approaches to pipeline development
- Pipeline progress through drug discovery / pre-clinical / clinical stages / market approval
 - Closure of fundraises and strategic financing rounds
 - Key stages of strategic development / partnerships
- Implementation of new technologies, processes for strategic advantage

Highly commended and winner presented by Jill Richardson, Senior Director, Discovery Research, MSD

FINALISTS

AMEPHARMA

ARVELLE
THERAPEUTICSastex
pharmaceuticals

Galapagos



Immatics

SANIFIT

scandinavian
biopharmaSHIELD
THERAPEUTICS

Hosted by



This award recognises a European Medtech (device, surgical, diagnostic) company that has demonstrated superior excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community.

Qualifying criteria

- Open to all Medtech / Medical Device companies with European Headquarters
- Open to all Medtech companies with a market capitalisation that is \$10bn or less.
- Submission relates to activities achieved in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Targeting of unmet medical need / use of innovative approaches to product development
- Pipeline progress through in-development / clinical stages / market approval
 - Closure of fundraises and strategic financing rounds
 - Key stages of strategic development / partnerships
- Implementation of new technologies, processes for strategic advantage

Highly commended and winner presented by Chris Coe, EVP, Executive Search, Talentmark

FINALISTS



The only talent partner you need

Delivering exceptional leaders to exceptional companies worldwide since 1971

London – Boston – Basel – Frankfurt – Shanghai

Talentmark Head Office: Capital Tower, 91 Waterloo Road, London SE1 8RT

T: +44 (0) 345 095 2626 | E: info@talentmark.com | www.talentmark.com

Your next deal of a lifetime.
Your Venue®.

The deal of a lifetime is yours for the making.

And Venue® virtual data room gives you what you need to close it.

Venue's rigorous, multi-level security enables you to confidently share critical information in real time. It's backed by 24/7 support from our global professional services team. And now, it also helps accelerate your dealmaking by enabling you to:

- **Upload 30% faster** while you complete other vital work
- **Decide more quickly** with intuitive, calendar-view tracking of reports, data and insights.
- **Gain stakeholder confidence** with easier to navigate Q&A.

Hosted by



This award recognises a European Healthtech (digital health, digital therapeutics, databases, applications and wearables) company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for consumer, patients, investors, employees and the broader life science community.

Qualifying criteria

- Open to all Healthtech companies with European Headquarters
- Open to all Healthtech companies with a market capitalisation that is \$10bn or less.
- Submission relates to activities achieved in the period between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Targeting of unmet medical need / use of innovative approaches to product development
 - Pipeline progress through in-development / clinical stages / market approval
 - Closure of fundraises and strategic financing rounds
 - Key stages of strategic development / partnerships
- Implementation of new technologies, processes for strategic advantage

Highly commended and winner presented by Matthew Gould, EMEA Head, Donnelley Financial Solutions

FINALISTS

BenevolentAI

IXICO

Kaiku
HEALTH



medopad

oxfordvr
Immersive technology for mental health



SOLVE
CARE

Jefferies

The Global Leader
in Biotech and Pharma
Investment Banking



PRIVATE COMPANY CEO OF THE YEAR

Hosted by **Jefferies**

This award recognises a private company CEO that has demonstrated truly outstanding and exemplary leadership in their respective companies.

Qualifying criteria

- Open to CEOs of privately owned life science companies
- Period to be judged review is between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Career achievements and leadership qualities
- How the CEO has created value for investors
- What the CEO's greatest achievements were in this period
- Creation of new partnerships / leveraging existing partnerships
- What the CEO has done to influence and advance the wider life science industry

Highly commended and winner presented by Gil Bar Nahum, Managing Director, Jefferies

FINALISTS



Catherine Pickering
CEO
iOnctura



Erik van den Berg
CEO
AM-Pharma



Mark Altmeyer
CEO
Arvelle
Therapeutics



Ugur Sahin
CEO
BioNTech

The Global Leader in Biotech and Pharma Investment Banking

Leading Biotech Equity Franchise

Leading Equity Franchise

- Jefferies is the #1 bookrunner in biotech and pharma common stock offerings, having bookrun over 395 deals since 2010, 30% more than our closest competitor
- For the 3rd year in a row Institutional Investor survey ranks Jefferies as having the top healthcare equity sales force
- Since the beginning of 2015, Jefferies has participated in 60+ biotech IPOs for over \$7.3 billion in total proceeds

Global Franchise

- Since 2016, Jefferies has completed 50+ Life Sciences IPOs
- Since 2010, Jefferies has completed 80+ ex-US biotech and pharma M&A transactions

Leading Biotech and Pharma M&A Franchise

Strong Momentum

- Since 2015, Jefferies has announced over 80 M&A transactions in the biotech and pharma sectors with an aggregate value of over \$80 billion
- Jefferies has represented a range of mid- and large-cap companies, including Eli Lilly, Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and Takeda

Global Franchise

- Jefferies has represented biotech and pharma clients across the US, UK, Italy, China, Japan, Greece, India, South Africa, and Chile, among others



Hosted by

Jefferies

This award recognises a publicly-listed company CEO that has demonstrated truly outstanding and exemplary leadership in their respective companies.

Qualifying criteria

- Open to CEOs of publicly owned life science companies
- Period to be judged review is between 1 September 2018 and 1 September 2019

Judges paid particular attention to:

- Career achievements and leadership qualities
- How the CEO has created value for shareholders and investors
- What the CEO's greatest achievements were in this period
- Creation of new partnerships / leveraging existing partnerships
- What the CEO has done to influence and advance the wider life science industry

Highly commended and winner presented by Gil Bar Nahum, Managing Director, Jefferies

FINALISTS



Emma Walmsley
CEO
GSK



Jan Moller
Mikkelsen
CEO and President
Ascendis Pharma



Jan van de Winkel
CEO and President
Genmab



Onno van de Stolpe
CEO
Galapagos

October 2019 Phathom™ PHARMACEUTICALS \$209,000,000 Initial Public Offering Lead-Left Bookrunner	October 2019 HERON THERAPEUTICS \$150,000,000 Common Stock Offering Joint Bookrunner	September 2019 Fote THERAPEUTICS \$173,000,000 Common Stock Offering Lead-Left Bookrunner	October 2019 Progenics <i>First Fight and Follow!</i> \$524,000,000 Sale to Lantheus Holdings, Inc. Sole Financial Advisor	September 2019 Pending Dova PHARMACEUTICALS \$915,000,000 Sale to Swedish Orphan Biovitrum AB Lead Financial Advisor	July 2019 RECORDATI \$390,000,000 Acquisition of rights to Signifor® and Osilodrostat from Novartis Sole Financial Advisor
September 2019 igm biosciences™ \$201,000,000 Initial Public Offering Lead-Left Bookrunner	August 2019 deciphera \$460,000,000 Common Stock Offering Joint Bookrunner	July 2019 Ra Pharma \$150,000,000 Common Stock Offering Lead-Left Bookrunner	January 2019 Elanco \$245,000,000 Acquisition of Aratana Therapeutics Sole Financial Advisor	January 2019 SPECTRUM PHARMACEUTICALS \$300,000,000 Sale of Marketed Oncology Portfolio to Acrotech Biopharma Sole Financial Advisor	December 2018 Bristol-Myers Squibb \$1,600,000,000 Sale of UPSA Consumer Health Business to Taisho Pharmaceutical Joint Financial Advisor
July 2019 Genmab \$582,000,000 Initial Public Offering Joint Bookrunner	June 2019 odonate PHARMACEUTICALS \$142,000,000 Common Stock Offering Lead-Left Bookrunner	June 2019 oncopeptides \$78,000,000 Common Stock Offering Joint Bookrunner	November 2018 sobi <i>Pioneer in Rare Diseases</i> \$1,500,000,000 Acquisition of Synagis® US rights and rights to participate in future earnings of MED18897 in the US from AstraZeneca Plc Sole Financial Advisor	October 2018 ENDOCYTE \$2,101,000,000 Sale to Novartis AG Joint Financial Advisor	June 2018 RECORDATI \$3,505,000,000 Sale of FIMEI SpA to CVC Capital Partners Sole Financial Advisor
June 2019 bridgebio \$401,000,000 Initial Public Offering Joint Bookrunner	April 2019 Autolus \$116,000,000 Common Stock Offering Joint Bookrunner	September 2017 nightstar PHARMACEUTICALS \$121,000,000 Initial Public Offering Lead-Left Bookrunner	May 2018 ARMO BIOSCIENCES \$1,600,000,000 Sale to Eli Lilly Joint Financial Advisor	October 2017 Kite \$3,900,000,000 Sale to Novartis AG Sole Financial Advisor	August 2017 Kite \$11,900,000,000 Sale to Gilead Joint Financial Advisor



EXECUTIVE DINNER AND REGIONAL AWARDS CEREMONY

5th Annual Awards Ceremony

November 17, 2020
London



INDUSTRY CONTRIBUTION AWARD

Hosted by



The network
for life science
executive leaders

This award is a single honour and recognises the contribution of an individual during their most recent prominent leadership role and their wider contribution to the industry as a whole.

The recipient of the 2019 Industry Contribution Award is

Britt Meelby Jensen, CEO, Atos Medical

Britt Meelby Jensen, joined Atos Medical in March 2019 as Chief Executive Officer. Prior to this role, Ms Jensen held the role of CEO at Danish biotech; Zealand Pharma from January 2015, leaving her to take up her position at Atos Medical.

She has been called the Danish biotech queen and has enjoyed leading, setting ambitious goals and accelerating company growth all throughout her career.

Ms Jensen left Zealand in a strong financial position with an exceptional outlook for the coming years. Under Ms Jensen's leadership, Zealand transformed into a company with a late-stage proprietary pipeline, a highly competent organisation, a dual listing and physical presence in the U.S. as well as multiple future value drivers.

Presented by Neil Darkes, Co-CEO, LSX Ltd.





LONGEVITY LEADERS

WORLD CONGRESS

AGEING SCIENCE | AGEING WELL | LONGEVITY RISK

2nd Annual Congress

21-22 April 2020
133 Houndsditch Liverpool St.
London, UK

www.longevityleaders.com #longevityleaders @longevityleader

Created by



Connect
with
purpose



LIFETIME ACHIEVEMENT AWARD

Hosted by



LONGEVITY
LEADERS

This award is a single honour and recognises the achievements of an individual during their whole career and their wider contribution to the industry as a whole.

The recipient of the 2019 Lifetime Achievement Award is

Dame Louise Makin MBA, DBE

Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004 and led the transformation of BTG from \$150m value to acquisition by Boston Scientific for \$4.2 billion in August 2019 by successfully acquiring and integrating 8 companies into BTG to create a leading Interventional Medicine Business. Louise is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust, a Trustee of the Outward Bound Trust, Chair of the 1851 Trust, and an Honorary Fellow of St. John's College.

From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.

Presented by Angela Sands, SVP, Longevity Leaders



#lifestarsawards





ATTENDING COMPANIES

Abingworth LLP	BioNTech	Enterome	Inivata
Achilles Tx	BioNTech SE	Enterprise Therapeutics Ltd	INKEF Capital
Agile Capital Markets	Black Belt Tx	Enzyre	Instinctif
Alacrita Consulting	Bloomberg Intelligence	EpiEndo	Instinctif Partners
Alacrita Consulting Ltd	BNY Mellon	ERYTECH	InterNA Technologies
Albion Capital	Branding Science	EUSA Pharma	IO Biotech
Alderley Park	Breath Therapeutics	Evercore	iOnctura
Alkermes	Bridge Valley Ventures	Evox Therapeutics	Ipsen Pharma
Allegra Therapeutics	Bridgehead	Exscientia	IQ Capital Partners
AM-pharma	Bruntwood SciTech	F-Star	IXICO
AMRA Medical	C4x Discovery	finnCap	IXICO PLC
Angiostatix	Calliditas Therapeutics	FINOVAM GESTION	JCI Capital Ltd
Apeiron Biologics	Camallergy	FirstWord MedTech	Jefferies
Apellis Pharmaceuticals	Capricorn Partners	Forbion	Johnson & Johnson Innovation
Apollo Ventures	Cascara Ventures	Fountain Health Partners	Juvenescence Ltd
Arctoris	Castor EDC	Freelance	Kaiku Health
Arctoris Ltd	Catalytic Life Sciences	FTI Consulting	KBC Securities
Arix Bioscience	Censo Biotechnology	Futura Medical plc	Kempen
Arthur J Gallagher	Chelse & Westminster Hospital NHS Trust	Galapagos	Kreos Capital
Artios Pharma Ltd	Chronomics	Galecto	Kurma Partners
ARUK	Citigate Dewe Rogerson	Genmab	Kymab
Arvelle Therapeutics	Closed Loop Medicine	GenSearch	L.E.K Consulting
Asabys Partners	CMS	GJE Intellectual Property	LATTICE MEDICAL
Ascelia Pharma AB	CMS Cameron McKenna Nabarro Olswang	GlaxoSmithKline	Liva Healthcare
Ascendis Pharma	LLP	GlobalData	Locate Bio
Astellas Pharma	Confluence Tax	Goodwin	Locust Walk
Astex Pharmaceuticals	Congenica	Grey Wolf Therapeutics	Longevity Leaders
Atlantic Therapeutics	Consilium Strategic Communications	HalioDx	LSP
Atos Medical	Covington	Hemogenyx Pharmaceuticals plc	Macrophage
Autifony	Crick Institute	High-Tech Gruenderfonds HTGF	Mail on Sunday
Babylon Health	CTI Life Sciences	Hookipa Pharma	Mallinckrodt Ltd
Bank of America Merrill Lynch	DC4U	Hyloris	Marks & Clerk
Barclays Bank plc	Delta4	Ignite Capital Partners, Inc	Medicxi
BDO	DepYmed, Inc.	Illustratum	Medopad
BeeSpoke Strategy	Deutsche Bank	Illustratum	Medopad Ltd.
Bellicum Pharma	DFIN	Immatics Biotechnologies	Mercer
BenevolentAI	DH Life Sciences LLP (a Danaher Company)	Immunicum	Mereo BioPharma
BetaGlue Technologies	Dyadic International Inc.	ImplantData	Mills-Reeve
BIA Separations	E-Therapeutics	Inflazome	Mintz
BicycleTX Ltd	Eli Lilly	Inflazome Ltd	MiroBio
BioArctic	Eli Lilly and Company	Informa	Mission Therapeutics
BioArctic AB	Elypta	Informa - Medtech Insight	Mogrify
Bioinvent Intl	Endostart srl	Informa Pharma Intelligence	Molecular Partners AG



Montrose Capital Partners	Rothschild & Co.
Morgan Prestwich	Scandinavian Biopharma
MSD	Sensyne Health
My Online Therapy	Seroba Life Sciences
MYBRAIN TECHNOLOGIES	Servier
Nasdaq	Seventure
NDA Group	Shield Therapeutics plc
Newcastle University	Silence Therapeutics
Norgine Ventures	Simbec-Orion
Novaliq GmbH	Skills Alliance
Novateur Ventures Inc	Sofinnova
Novo Holdings	Sol-Gel
Novo Ventures	SolasCure Ltd
OMass Therapeutics	Solve.Care
Oncimmune	Storm Therapeutics
Oncodesign	Surgify Medical
Optimum Strategic Communications	SV Health Investors
Orphazyme	SVB Leerink
Oryzon	Syncona Ltd
OWKIN	Syneos Health
Owlstone Medical	Syngene
Oxford Biomedica	Sysmex Corporation
Oxford VR	Talentmark
Panakes Partners	Teenage Cancer Trust
Pathfinder Medical	The Pension SuperFund
Peel Hunt	Themis
Perceptive	Touchlight Genetics
PhagoMed Biopharma GmbH	Treehill Partners
PharmaCytics	UCL
Phoremest Ltd	Uniphar
Primex Pharmaceuticals	University of Oxford
Procarta BioSystems	Vaccibody
Prokarium	Valenta Pharma
Promidian	Valiance AM
PsiOxus Therapeutics	ValoTx
Puhua Capital	Vantage
Quanta	VI Partners
Quell TX Ltd	Weatherden
R-Pharm, RBV Capital	Xenikos
RBC Capital Markets	Zambon
Rexgenero	Zilico
Roche/Genentech	Zinc
Roivant Sciences	Zyme Communications

